Xbrane Biopharma AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was SEK 61.83 million compared to SEK 7.33 million a year ago. Net loss was SEK 58.4 million compared to SEK 36.12 million a year ago.

Basic loss per share from continuing operations was SEK 2.1 compared to SEK 1.5 a year ago. Diluted loss per share from continuing operations was SEK 2.1 compared to SEK 1.5 a year ago. Basic loss per share was SEK 2.12 compared to SEK 1.44 a year ago.

Diluted loss per share was SEK 2.12 compared to SEK 1.44 a year ago.